New hope for rare blau syndrome: tofacitinib under the microscope
NCT ID NCT06688838
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at how well the drug tofacitinib works for people with Blau syndrome, a rare genetic condition that causes inflammation in the joints, eyes, and skin. Researchers will review medical records from 24 participants to see if tofacitinib helps control the disease. The goal is to find better treatment options for those who don't respond to standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib
- What this could lead to
- If successful, this could point toward a more effective treatment option for people with Blau syndrome who do not respond to standard therapies.
- What could go wrong
- This is a small, early-stage observational study with only 24 participants, so results may not apply to everyone. Tofacitinib may cause side effects like increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLAU SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yikai YU
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.